Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This gene is annotated as a *pseudogene* for the beta subunit (subunit 2) of eukaryotic translation initiation factor 2. The canonical, functional gene, **EIF2S2**, encodes a beta subunit critical for translation initiation and has roles in cell growth, stress response, and disease[2][4]. However, **EIF2S2P1** itself does not encode a functional protein and is not regarded as a therapeutic target. Pseudogenes like EIF2S2P1 are usually defective copies of functional genes, retaining similarity to their parental gene but lacking protein-coding ability due to disabling mutations. There is currently no evidence suggesting that EIF2S2P1 directly participates in molecular pathways, diseases, or drug interactions. If you intended to ask about the functional gene **EIF2S2** rather than **EIF2S2P1**, that gene is implicated as a prognostic marker and potential target in cancer research, including glioblastoma and hepatocellular carcinoma[2][4]. If so, clarification is recommended, as the two designations refer to distinct (functional vs. non-coding) genetic loci.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 2 subunit 2 beta pseudogene 1 (EIF2S2P1).